Total Valuation
Lotus Pharmaceuticals has a market cap or net worth of $96.05K. The enterprise value is $109.75K.
Market Cap$96.05K
Enterprise Value$109.75K
Share Statistics
Lotus Pharmaceuticals has 27,816,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding27,816,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Lotus Pharmaceuticals’s return on equity (ROE) is 0.17 and return on invested capital (ROIC) is -331.10%.
Return on Equity (ROE)0.17
Return on Assets (ROA)-3.31
Return on Invested Capital (ROIC)-331.10%
Return on Capital Employed (ROCE)0.17
Revenue Per Employee0.00
Profits Per Employee-80.74
Employee Count233
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Lotus Pharmaceuticals is ―. Lotus Pharmaceuticals’s PEG ratio is 0.00.
PE Ratio―
PS Ratio0.00
PB Ratio-103.17
Price to Fair Value-103.17
Price to FCF-598.56
Price to Operating Cash Flow0.00
PEG Ratio0.00
Income Statement
In the last 12 months, Lotus Pharmaceuticals had revenue of 0.00 and earned -18.81K in profits. Earnings per share was 0.00.
Revenue0.00
Gross Profit0.00
Operating Income-18.81K
Pretax Income-18.81K
Net Income-18.81K
EBITDA-18.81K
Earnings Per Share (EPS)0.00
Cash Flow
In the last 12 months, operating cash flow was -16.40K and capital expenditures 0.00, giving a free cash flow of -16.40K billion.
Operating Cash Flow-16.40K
Free Cash Flow-16.40K
Free Cash Flow per Share>-0.01
Dividends & Yields
Lotus Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-1.96
52-Week Price Change―
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)82.51K
Important Dates
Lotus Pharmaceuticals upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Lotus Pharmaceuticals as a current ratio of 0.05, with Debt / Equity ratio of 0.00%
Current Ratio0.05
Quick Ratio0.05
Debt to Market Cap0.01
Net Debt to EBITDA-6.10
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Lotus Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Lotus Pharmaceuticals EV to EBITDA ratio is -614.91, with an EV/FCF ratio of -604.56.
EV to Sales0.00
EV to EBITDA-614.91
EV to Free Cash Flow-604.56
EV to Operating Cash Flow-604.56
Balance Sheet
Lotus Pharmaceuticals has $419.00 in cash and marketable securities with $123.43K in debt, giving a net cash position of -$123.01K billion.
Cash & Marketable Securities$419.00
Total Debt$123.43K
Net Cash-$123.01K
Net Cash Per Share>-$0.01
Tangible Book Value Per Share>-$0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Lotus Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―